Case Reports:

Complete response in a patient with liver metastases from breast cancer employing hepatic arterial infusion 5-fluorouracil based chemotherapy plus systemic nab-paclitaxel

Girolamo Ranieri _, Ilaria Marech, Mariangela Porcelli, Francesco Giotta, Gennaro Palmiotti, Giuseppe Laricchia, Vito Fazio and Cosmo Damiano Gadaleta

PDF  |  HTML  |  How to cite

Oncotarget. 2018; 9:8197-8203. https://doi.org/10.18632/oncotarget.23793

Metrics: PDF 1381 views  |   HTML 5191 views  |   ?  


Girolamo Ranieri1, Ilaria Marech1, Mariangela Porcelli1, Francesco Giotta1, Gennaro Palmiotti1, Giuseppe Laricchia1 , Vito Fazio1 and Cosmo Damiano Gadaleta1

1 Interventional and Medical Oncology Unit, National Cancer Research Center, Istituto Tumori Giovanni Paolo II, Viale Orazio Flacco, Bari, Italy

Correspondence to:

Girolamo Ranieri, email:

Keywords: hepatic intra-arterial chemotherapy; nab-paclitaxel; liver metastases; breast cancer

Received: November 06, 2017 Accepted: December 11, 2017 Published: December 31, 2017


About half of patients with metastatic breast cancer (mBC) have unresectable liver metastases (LMs) or liver-predominant disease (LPD). Unfortunately systemic chemotherapy has limited tumor response due to LMs are supplied by hepatic artery. Hepatic intra-arterial (HAI) have antitumor activity in pretreated patients with LMs. Here we report the case of a 55-year-old woman affected by BCLPD and heavily pretreated. LMs responded to treatment based on HAI with 5-fluorouracil and nab-paclitaxel systemic chemotherapy, and they completely disappeared on a CT-scan. We conclude that this combination chemotherapy is safe and may be very useful for the treatment of patients with BCLPD. Therefore, this combination should be evaluated in a large study.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 23793